Past Trials

Showing 1 - 10 of 159

  • Page of 16
  • Next >

  • Lung Cancer CA209370

    May 09, 2017

    The purpose of this study is to determine whether Nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.

  • Lung Cancer GO29537

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, multicenter, open-label study which is designed to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with Carboplatin + Nab-Paclitaxel compared with treatment with Carboplatin + Nab-Paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).

  • Metastatic/Locally Advanced Solid Tumors EMR200647-001

    May 09, 2017

    The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks in patients with metastatic or locally advanced solid tumors.

  • Lung Cancer GO29527

    May 09, 2017

    This study is for participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC). Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, global, multicenter, open-label, study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of Atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC).

  • Castration-Resistant Prostate Cancer (Trumpet-ONC-MA-1004)

    May 09, 2017

    The purpose of this study is to describe patterns of care in CRPC (Castration-Resistant Prostate Cancer) patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.

  • Solid Tumors/Lymphomas

    May 09, 2017

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

  • Lung Cancer 20070782

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this double-blind, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV.

  • Venous Thromboembolism (VTE) 39039039STM4001 (BAY 59-7939)

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this multicenter, double-blind, placebo-controlled, parallel-group, superiority study comparing the efficacy and safety of Rivaroxaban with placebo for primary prophylaxis of venous thromboembolism (VTE) in ambulatory adult participants, with various cancer types who are scheduled to initiate systemic cancer therapy.

  • Lung Cancer B7391003

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this multinational, double-blind, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of Bevacizumab-Pfizer plus Paclitaxel and Carboplatin versus Bevacizumab-EU plus Paclitaxel and Carboplatin in first-line treatment for patients with advanced non-squamous NSCLC.

  • Localized Spine Metastasis 0631

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this phase II/III trial studying how well image-guided radiosurgery or stereotactic body radiation therapy works and compares it to external-beam radiation therapy in treating patients with localized spine metastasis.


Showing 1 - 10 of 159

  • Page of 16
  • Next >
MSK_ClinicalTrials_Ad